Marina joined Ampersand in 2013. Prior to joining Ampersand, she was an Associate Director in Healthcare Investment Banking at UBS where she worked on a number of leveraged buyouts, mergers and acquisitions, and debt and equity financings for middle market healthcare companies. Marina’s current and past board seats include GeneWerk, Gyros PTI, Protagene, and Vibalogics. Marina holds a B.A. with Honors from Wellesley College where she majored in Biological Chemistry and International Relations. After finishing her degree, she worked at biochemistry laboratories at Harvard Medical School.